Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.436
Neutral
RSI(14)
41.640
Neutral
STOCH(KDJ)(9,3,3)
40.506
Sell
ATR(14)
2.165
High Vlolatility
CCI(14)
-128.424
Sell
Williams %R
85.395
Oversold
TRIX(12,20)
0.011
Sell
StochRSI(14)
0.000
Sell
Search
Biontech SE
BNTXAdd to Watchlist
89.330USD
-2.730-2.97%
Close 07-24 16:00（ET）Quotes delayed by 15 min
22.59BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-2.97%
5 Days
-2.35%
1 Month
-0.74%
6 Months
-22.98%
Year to Date
-6.17%
1 Year
-22.53%
Key Figures
92.000Open
92.190High
886.10KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.35%Turnover Ratio
92.060Prev. Close
88.920Low
52.44MTurnover
LossP/E Static
1.03P/B
0.00%Div Yield TTM
-5.93%ROA
124.00052wk High
1.34Volume Ratio
-665.30MNet Profit
252.88MShares
-4.3892EPS TTM
1.33Beta
-6.66%ROE
79.52052wk Low
3.55%Amplitude
40.47%Gross Margin
22.59BMarket Cap
0.47Reward/Risk
1.95%Risk Rate
TradingKey Stock Score of Biontech SE
Currency: USD Updated: 2026-07-24Key Insights
Biontech SE's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 82 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 127.65.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Biontech SE's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Biontech SE Highlights
StrengthsRisks
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Fairly Valued
The company’s latest PE is -20.35, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 51.86M shares, decreasing 2.43% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 122.26K shares of this stock.
Analyst Rating
Based on
22
analysts
Buy
Current Rating
127.650
Target Price
+38.66%
Upside Space
Biontech SE News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
22
analysts
Buy
Current Rating
127.650
Target Price
+38.66%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Biontech SE
BNTX
22
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
91.542
Sell
MA10
91.321
Sell
MA20
92.471
Sell
MA50
91.150
Sell
MA100
93.370
Sell
MA200
98.523
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Biontech SE Info
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Ticker SymbolBNTX
CompanyBiontech SE
CEOSahin (Ugur)
Websitehttps://www.biontech.com/
Shareholders
Related Instruments
+0.88%
+1.60%
+0.43%
+0.90%
+0.46%
-0.72%
+1.22%
+1.25%
-1.18%
-0.12%
+0.94%
+0.90%
+1.20%
-0.02%
+2.04%
0.00%
+0.63%
-0.69%
+2.59%
+0.89%Popular Instruments
51900.000
+176.000 (+0.34%)
28150.400
-427.600 (-1.50%)
7408.100
-11.800 (-0.16%)
14948.000
-153.000 (-1.01%)
64219.000
-1152.000 (-1.76%)
6264.500
+48.800 (+0.79%)
90.043
-2.069 (-2.25%)
333.020
+11.360 (+3.53%)
206.840
-1.920 (-0.92%)
4052.350
+2.980 (+0.07%)
FAQs
What is the current price of Biontech SE (BNTX)?
The current price of Biontech SE (BNTX) is 89.33.
What is the symbol of Biontech SE?
The ticker symbol of Biontech SE is BNTX.
What is the 52-week high of Biontech SE?
The 52-week high of Biontech SE is 124.00.
What is the 52-week low of Biontech SE?
The 52-week low of Biontech SE is 79.52.
What is the market capitalization of Biontech SE?
The market capitalization of Biontech SE is 22.59B.
Is Biontech SE (BNTX) currently rated as Buy, Hold, or Sell?
According to analysts, Biontech SE (BNTX) has an overall rating of Buy, with a price target of 127.65.
What is the Earnings Per Share (EPS TTM) of Biontech SE (BNTX)?
The Earnings Per Share (EPS TTM) of Biontech SE (BNTX) is -5.52.